Works about OVARIAN cancer treatment

Results: 1423
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Hutchinson's sign.

    Published in:
    Portuguese Journal of Dermatology & Venereology, 2023, v. 81, n. 2, p. 145, doi. 10.24875/PJDV.23000019
    By:
    • Mansilla-Polo, Miguel;
    • Navarro-Mira, Miguel A.;
    • Botella-Estrada, Rafael
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Ovarian teratoma in a dog.

    Published in:
    Turkish Journal of Veterinary & Animal Sciences, 2012, v. 36, n. 5, p. 573, doi. 10.3906/vet-1103-31
    By:
    • GÜLÇUBUK, Ahmet;
    • ALTUN, Elif Demet;
    • BOZKURT, Erol Rüştü;
    • SONTAŞ, Besim Hasan;
    • HAKTANIR, Damla
    Publication type:
    Article
    21
    22
    23
    24
    25
    26
    27

    Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

    Published in:
    2018
    By:
    • King, Madeleine T.;
    • Stockler, Martin R.;
    • O’Connell, Rachel L.;
    • Buizen, Luke;
    • Joly, Florence;
    • Lanceley, Anne;
    • Hilpert, Felix;
    • Okamoto, Aikou;
    • Aotani, Eriko;
    • Bryce, Jane;
    • Donnellan, Paul;
    • Oza, Amit;
    • Avall-Lundqvist, Elisabeth;
    • Berek, Jonathan S.;
    • Sehouli, Jalid;
    • Feeney, Amanda;
    • Berton-Rigaud, Dominique;
    • Costa, Daniel S. J.;
    • Friedlander, Michael L.;
    • for the GCIG Symptom Benefit group
    Publication type:
    journal article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37

    Chromatin Binding of <italic>c</italic>-REL and p65 Is Not Limiting for Macrophage <italic>IL12B</italic> Transcription During Immediate Suppression by Ovarian Carcinoma Ascites.

    Published in:
    Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01425
    By:
    • Unger, Annika;
    • Finkernagel, Florian;
    • Hoffmann, Nathalie;
    • Neuhaus, Felix;
    • Joos, Barbara;
    • Nist, Andrea;
    • Stiewe, Thorsten;
    • Visekruna, Alexander;
    • Wagner, Uwe;
    • Reinartz, Silke;
    • Müller-Brüsselbach, Sabine;
    • Müller, Rolf;
    • Adhikary, Till
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44
    45

    LNK (SH2B3): paradoxical effects in ovarian cancer.

    Published in:
    Oncogene, 2015, v. 34, n. 11, p. 1463, doi. 10.1038/onc.2014.34
    By:
    • Ding, L-W;
    • Sun, Q-Y;
    • Lin, D-C;
    • Chien, W;
    • Hattori, N;
    • Dong, X-M;
    • Gery, S;
    • Garg, M;
    • Doan, N B;
    • Said, J W;
    • Xiao, J-F;
    • Yang, H;
    • Liu, L-Z;
    • Meng, X;
    • Huang, R Y-J;
    • Tang, K;
    • Koeffler, H P
    Publication type:
    Article
    46

    An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).

    Published in:
    Cancer Research & Treatment, 2018, v. 50, n. 1, p. 195, doi. 10.4143/crt.2016.376
    By:
    • Shin-Wha Lee;
    • Yong-Man Kim;
    • Chi Heum Cho;
    • Young Tae Kim;
    • Seok Mo Kim;
    • Soo Young Hur;
    • Jae-Hoon Kim;
    • Byoung-Gie Kim;
    • Seung-Cheol Kim;
    • Hee-Sug Ryu;
    • Soon Beom Kang
    Publication type:
    Article
    47
    48
    49
    50